Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitors. Herein, we determined the prognostic value of p...

Full description

Bibliographic Details
Main Authors:	Kosuke Ueda, Naoyuki Ogasawara, Naoki Ito, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Journal of Clinical Medicine
Subjects:	renal cell carcinoma immune checkpoint inhibitor nivolumab plus ipilimumab lymphocyte count
Online Access:	https://www.mdpi.com/2077-0383/12/6/2417

Similar Items

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
by: Takeshi Fukumoto, et al.
Published: (2022-08-01)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
by: Mikako Nakamura, et al.
Published: (2023-02-01)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
by: Rebecca Charles, et al.
Published: (2023-09-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
by: M. A. Lyadova, et al.
Published: (2021-12-01)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
by: Omid Kooshkaki, et al.
Published: (2020-06-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023-03-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
by: Yoshiyuki Nakamura, et al.
Published: (2021-02-01)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
by: Brendan John Guercio, et al.
Published: (2021-03-01)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
by: Jingjie Chen, et al.
Published: (2020-07-01)

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab
by: Yusuke Yano, et al.
Published: (2022-11-01)

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
by: Hiroshi Sawayama, et al.
Published: (2022-12-01)

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
by: Amr Mohamed, et al.
Published: (2022-05-01)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)

Bilateral corneal perforation in Ipilimumab/Nivolumab - associated peripheral ulcerative keratitis
by: Julia Aschauer, et al.
Published: (2022-12-01)

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023-12-01)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
by: Julia Katharina Schwarze, et al.
Published: (2022-01-01)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
by: Renata Pacholczak-Madej, et al.
Published: (2022-10-01)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
by: Xin Zhao, et al.
Published: (2022-06-01)

Paraganglioma of the urinary bladder: Case report and literature review
by: Hirofumi Kurose, et al.
Published: (2020-09-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022-07-01)

Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings
by: Jessica C. Lee, et al.
Published: (2020-11-01)

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
by: Adeel Masood, et al.
Published: (2021-12-01)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020-05-01)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
by: Ahmad A. Tarhini, et al.
Published: (2022-11-01)

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
by: Hannah L. Buckley, et al.
Published: (2019-11-01)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
by: Liu Yang, et al.
Published: (2023-10-01)

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
by: Andrey Moiseyenko, et al.
Published: (2020-11-01)

Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
by: Viraj A. Master, et al.
Published: (2023-01-01)

Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
by: Hiroaki Satoh, et al.
Published: (2022-06-01)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
by: Hélène Salaün, et al.
Published: (2022-12-01)